CD8A and B-cell non-Hodgkin lymphoma: In this preclinical model, CD4+ and CD8+ T cells mediate immune control over EBV infection and B-cell lymphoma development (Strowig et al., 2009) and protective EBV-specific CD4+ T cells can be primed with vaccine candidates (Gurer et al., 2008; Meixlsperger et al., 2013).